Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Scilex Holding Company | SCLX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.85 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 0.8002 - 8.3699 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 0.85 | USD |
Scilex Holding Company Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
141.26M | 166.19M | - | 46.74M | -114.33M | -0.69 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Scilex News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SCLX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.16 | 1.18 | 0.8002 | 0.9010897 | 1,644,890 | -0.31 | -26.72% |
1 Month | 1.60 | 1.70 | 0.8002 | 1.19 | 1,042,076 | -0.75 | -46.88% |
3 Months | 1.65 | 2.63 | 0.8002 | 1.42 | 1,047,693 | -0.80 | -48.48% |
6 Months | 1.83 | 2.63 | 0.8002 | 1.45 | 965,213 | -0.98 | -53.55% |
1 Year | 6.85 | 8.3699 | 0.8002 | 2.56 | 817,693 | -6.00 | -87.59% |
3 Years | 10.05 | 16.20 | 0.8002 | 3.62 | 669,189 | -9.20 | -91.54% |
5 Years | 10.05 | 16.20 | 0.8002 | 3.62 | 669,189 | -9.20 | -91.54% |
Scilex Description
Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. ZTlido (lidocaine topical system) 1.8% is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of neuropathic pain associated with post-herpetic neuralgia. We have acquired two FDA approved non-opioid pain products, GLOPERBA and ELYXYB, for the treatment of gout in adults and oral solution for the acute treatment of migraine, with or without aura, in adults. Our product candidates include SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA TM), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, SP-103 (lidocaine topical system) 5. |